Man & Science closes €7.4 million capital increase

Liège, Belgium — 22 September 2021 — Man & Science SA, a privately held medical device company developing innovative neuromodulation solutions for neurological and headache disorders, today announced the successful completion of a €6 million extension of the Series-A financing round. The investment will support initiation of the company’s Occipital Nerve Stimulation (ONS) pilot clinical study and accelerate development of its next generation injectable neurostimulation platform, designed to expand access to minimally invasive therapies for underserved patients.

The financing reflects strong confidence from both existing and new investors in Man & Science’s technology, clinical roadmap, and ability to deliver on key development milestones. The funds will support a pilot study evaluating the safety and feasibility of ONS therapy, while further advancing the company’s proprietary injectable neurostimulation system. This next generation device is designed to simplify implantation procedures, reduce patient burden, and broaden access to neurostimulation treatments for individuals with limited therapeutic options.

“This investment is a strong vote of confidence in our team, our technology, and our mission,” said Hugues Wallemaq, CEO of Man & Science. “It enables us to advance our ONS clinical program and continue the development of our injectable neurostimulation platform with the goal of delivering simpler, more accessible solutions for patients who currently have few effective options.”

Robert Taub, Chairman of the Board, added:

“We remain firmly committed to Man & Science’s long term vision and are encouraged by the progress the team continues to make. This financing underscores our sustained support and our strong belief in the company’s ability to accelerate development and bring next generation neurostimulation technologies to the patients who need them most.”